To review the safety of the recent oral lyophilisate formulation of desmopressin (MELT) in the pharmacological therapy for nocturnal enuresis (NE) and diabetes insipidus in pediatric patients. We searched for published reviews and references from PubMed- MEDLINE, Embase, and CENTRAL and did also a new search spanning the period Jan 1, 2000, until July 31, 2017 by using the terms MELT enuresis, MELT desmopressin, sublingual desmopressin, lyophilisate desmopressin. We evaluated all studies about side effects and effectiveness of MELT in pediatric patients.Twelve articles were analyzed with 1275 pediatric patients (<18 years old). The indication was enuresis in 1269 patients and central diabetes insipidus in 6 patients. In 11 studies desmopres...
Purpose: Desmopressin is a well established and effective therapy for nocturnal enuresis. Water into...
To investigate whether a structured withdrawal program from a sublingual formulation of fast-melting...
For a new formulation of a drug, only pharmacokinetic bioequivalence with the original formulation h...
To review the safety of the recent oral lyophilisate formulation of desmopressin (MELT) in the pharm...
Nocturnal enuresis (NE) is a common disorder in childhood and desmopressin is one of the most widely...
Objective: The aim of this study was to evaluate adverse effects of oral desmopressin lyophilisate (...
Nocturnal enuresis (NE) is a common disorder in children. Choice of treatment depends on the frequen...
Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with no...
Primary nocturnal enuresis is a prevalent childhood condition that can persist into adulthood. Desmo...
To assess side effects of MELT monotherapy and MELT in association with oxybutynin in children suffe...
Objective To determine the pharmacodynamic properties of a new oral lyophilisate formulation of desm...
OBJECTIVE: To determine the pharmacodynamic properties of a new oral lyophilisate formulation of des...
It has recently became apparent that severe primary monosymptomatic nocturnal enuresis (MNE) has a w...
This pre-specified sub-study of the desmopressin response in primary nocturnal enuresis study (DRIP ...
OBJECTIVE: To investigate whether a structured withdrawal program from a sublingual formulation ...
Purpose: Desmopressin is a well established and effective therapy for nocturnal enuresis. Water into...
To investigate whether a structured withdrawal program from a sublingual formulation of fast-melting...
For a new formulation of a drug, only pharmacokinetic bioequivalence with the original formulation h...
To review the safety of the recent oral lyophilisate formulation of desmopressin (MELT) in the pharm...
Nocturnal enuresis (NE) is a common disorder in childhood and desmopressin is one of the most widely...
Objective: The aim of this study was to evaluate adverse effects of oral desmopressin lyophilisate (...
Nocturnal enuresis (NE) is a common disorder in children. Choice of treatment depends on the frequen...
Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with no...
Primary nocturnal enuresis is a prevalent childhood condition that can persist into adulthood. Desmo...
To assess side effects of MELT monotherapy and MELT in association with oxybutynin in children suffe...
Objective To determine the pharmacodynamic properties of a new oral lyophilisate formulation of desm...
OBJECTIVE: To determine the pharmacodynamic properties of a new oral lyophilisate formulation of des...
It has recently became apparent that severe primary monosymptomatic nocturnal enuresis (MNE) has a w...
This pre-specified sub-study of the desmopressin response in primary nocturnal enuresis study (DRIP ...
OBJECTIVE: To investigate whether a structured withdrawal program from a sublingual formulation ...
Purpose: Desmopressin is a well established and effective therapy for nocturnal enuresis. Water into...
To investigate whether a structured withdrawal program from a sublingual formulation of fast-melting...
For a new formulation of a drug, only pharmacokinetic bioequivalence with the original formulation h...